Navigation Links
Epeius Biotechnologies' REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation From the U.S. FDA
Date:2/28/2011

SAN MARINO, Calif., Feb. 28, 2011 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) announced today that the U.S. FDA has granted Phase 3 status for the Company's lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek out and destroy metastatic cancer. According to Dr. Maria Gordon, Chief Medical Officer of Epeius, "What this means, in terms of clinical development, is that the Rexin-G product, with its advanced GMP manufacturing, bio-processing, and final formulation, meets rigorous FDA standards for obtaining a marketing license in the future; and that Epeius Biotech can now proceed with its strategic, diversified Phase 3 drug development program for pancreatic cancer, osteosarcoma and soft tissue sarcoma."

In addition to these high-priority programs, Rexin-G has demonstrated significant anti-tumor activity in chemotherapy-resistant breast cancer, hormone-refractory prostate cancer, ovarian cancer, squamous cell carcinoma, and certain hematologic malignancies, such as large B-cell lymphoma.

Rexin-G® was granted accelerated approval for the treatment of all chemotherapy-resistant solid malignancies in the Republic of the Philippines in 2007. In the U.S.A., Rexin-G gained Orphan Drug Designation and market protections from the FDA for pancreatic cancer in 2003, followed by Orphan Drug Status for both osteosarcoma and soft tissue sarcoma in 2008.  More recently, Epeius Biotechnologies completed a series of Phase 1 and Phase 2 clinical trials in the U.S., establishing the thresholds for bioactivity and dose-dependent efficacy for Rexin-G against a number of otherwise intractable cancers, as well as the product's overall safety over extended survival times and a notable lack of either safety issues or dose-limiting toxicities.

With these development-stage accomplishments at hand, Epeius is gearing up to open a series of pivotal studies for both pancreatic cancer and sarcomas in the U.S., while continuing to advance the clinical utility and market development of Rexin-G worldwide. With the completion of the enabling platform development and the clinical validation of its foremost oncology product, Epeius Biotechnologies continues to lead the field of genetic medicine with the development of its product pipeline, which includes Reximmune-C, a tumor-targeted gene delivery system for 'personalized' cancer vaccinations, administered to stimulate a long-lasting anti-tumor immunity.

For further information about Epeius Biotechnologies, its lead products, and its clinical trials, please contact Erlinda M. Gordon, M.D., at egordon@epeiusbiotech.com.

  • Logo 72dpi: Send2PressNewswire.com/image/11-0228-epeiusbio_72dpi.jpg


This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Epeius Biotechnologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
2. Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California
3. Epeius Biotechnologies to Partner at BIO Investor Forum
4. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
5. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
6. Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
7. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
8. Reportlinker Adds Nanobiotechnologies- applications, markets and companies
9. TriLink BioTechnologies Launches CleanAmp™ 7-deaza-dGTP for GC-rich Target Amplification
10. Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics
11. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... Waxhaw, NC (PRWEB) , ... August 22, 2017 ... ... device company focused on the development and distribution of highly differentiated spinal implant ... Luke Maher brings 15 years of spinal device industry experience to ...
(Date:8/22/2017)... ... August 22, 2017 , ... One of ... the practice of opioid-dose sparing. Opioid-dose sparing refers to the reduction of opioid ... with non-steroidal anti-inflammatory drugs (NSAIDs). , The potential for new therapies to replace ...
(Date:8/22/2017)... MA (PRWEB) , ... August 22, 2017 , ... ... new service pipeline built upon patented KBioBox technology, the extended GUIDE-Seq ananlysis. KBioBox ... source GUIDE-Seq computation pipeline to be provide scientists with easy to understand reports, ...
(Date:8/21/2017)... (PRWEB) , ... August 20, 2017 , ... ... Journal of Biomedical Optics (JBO) starting 1 January 2018. The journal is published ... Biomedical Optics publishes papers on the use of modern optical technology for improved ...
Breaking Biology Technology:
(Date:8/15/2017)...   ivWatch LLC , a medical device company focused on ... receipt of its ISO 13485 Certification, the global standard for medical ... Standardization (ISO®). ... Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as ...
(Date:7/20/2017)... 2017 Delta (NYSE: DAL ) customers now can ... at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan ... Delta,s biometric boarding pass experience that ... now integrated into the boarding process to allow eligible Delta SkyMiles Members ...
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
Breaking Biology News(10 mins):